ABIVAX Société Anonyme (EPA:ABVX)
France · Delayed Price · Currency is EUR | Market Cap | 8.95B |
| Revenue (ttm) | 5.31M |
| Net Income (ttm) | -293.52M |
| Shares Out | 77.83M |
| EPS (ttm) | -4.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,607 |
| Average Volume | 163,755 |
| Open | 117.40 |
| Previous Close | 120.40 |
| Day's Range | 114.20 - 120.00 |
| 52-Week Range | 4.51 - 128.40 |
| Beta | -0.26 |
| RSI | 56.66 |
| Earnings Date | Dec 15, 2025 |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]
Financial Performance
In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.
Financial StatementsNews
Unpacking the Latest Options Trading Trends in Abivax
Investors with a lot of money to spend have taken a bearish stance on Abivax (NASDAQ: ABVX). And retail traders should know. We noticed this today when the positions showed up on publicly available o...
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
Why Abivax Stock Was on Fire Today
Investors were excited about the possibility of a buyout with a high price tag.
Abivax is the top performing biotechnology stock YTD
List of the top 10 biotechnology stocks ranked by their year-to-date performance.
Abivax (ABVX) Rises Significantly with 17.5% Gain
Abivax (ABVX) Rises Significantly with 17.5% Gain
Abivax (ABVX) Stock Jumps Over 16% in Market Boost
Abivax (ABVX) Stock Jumps Over 16% in Market Boost
Abivax (ABVX) Joins Nasdaq Biotechnology Index
Abivax (ABVX) Joins Nasdaq Biotechnology Index
Abivax to be Added to Nasdaq Biotechnology Index
Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinic...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Europe's best-performing stock is up 1,400% this year. Here's what next
Abivax stock has far outperformed the broader index with a stellar performance, even as the company is making big financial losses.
Citizens Raises Abivax (ABVX) Price Target to $131, Maintains Rating | ABVX Stock News
Citizens Raises Abivax (ABVX) Price Target to $131, Maintains Rating | ABVX Stock News
Abivax CEO: Looking for new partners in markets outside the U.S.
Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally.
Abivax (ABVX) Reports Q3 EPS Loss but Maintains Strong Cash Position
Abivax (ABVX) Reports Q3 EPS Loss but Maintains Strong Cash Position
Abivax GAAP EPS of -€2.10
Abivax 9-month Net Loss Widens On Higher R&D Costs, Lower Operating Income
(RTTNews) - ABIVAX SA (ABVX, AAVXF), a French clinical-stage biotechnology company, announced late Monday wider net loss for the first nine months of fiscal 2025, hurt by increased Research and Develo...
Earnings To Watch: Abivax SA (XPAR:ABVX) Reports Q3 2025 Result
Earnings To Watch: Abivax SA (XPAR:ABVX) Reports Q3 2025 Result
Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
What's Happening With French Biotech Abivax Stock On Wednesday?
Abivax SA’s (NASDAQ: ABVX) stock is trading higher on Wednesday. The stock reacted to market rumours that U.S. pharma giant Eli Lilly and Co (NYSE: LLY) could make an offer. • Abivax stock is chargi...
What's Happening With French Biotech Abivax Stock On Wednesday?
Abivax SA's (NASDAQ: ABVX) stock is trading higher on Wednesday. The stock reacted to market rumours that U.S. pharma giant Eli Lilly and Co (NYSE:LLY) could make an offer.
Abivax (ABVX) Shares Surge on Speculation of Eli Lilly Takeover
Abivax (ABVX) Shares Surge on Speculation of Eli Lilly Takeover
Eli Lilly acquisition rumors reportedly fuel Abivax rally
French biotech Abivax's shares climb on Eli Lilly bid rumors
French biotech company Abivax's shares jumped by 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly might be interested in bidding for the business.
2 Under-the-Radar Stocks That Have Soared This Year
TransMedics Group's revolutionary organ care system is driving its strong results. Abivax is a David among Goliaths, and its growth story might just be getting started.
Abivax (ABVX) Shares Surge 11% on Takeover Speculation
Abivax (ABVX) Shares Surge 11% on Takeover Speculation
Abivax gains amid takeover speculation
Abivax (ABVX) ADRs surge on takeover rumors, with AstraZeneca named as a potential bidder.